Top Markets
#1 Helium Helium +61.05%
#2 Seeker Seeker +36.78%
#3 Pons Pons +29.11%
#4 Zylo Ecosystem Zylo Ecosystem +27.38%
#5 TENDIES TENDIES +26.94%
#6 Bounce Bounce +21.20%
#7 UnifAI Network UnifAI Network +20.79%
#8 DAPPOS DAPPOS +14.63%
#9 Songbird Songbird +14.46%
#10 pipedog pipedog +14.20%
Coin of the day
Helium Helium
Settings
Language
ENGLISH
Currency
USD
Theme
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Rank in Stocks #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Share Price
$9.50
Last synced: 2025-01-08
Market Cap
$819.52M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Poseida Therapeutics, Inc. (PSTX)

Category

Healthcare
Revenue for Poseida Therapeutics, Inc. (PSTX)
Revenue in Sep 2024 TTM: $150.86M
According to Poseida Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is $150.86M. In 2022 the company made a revenue of $130.36M an increase over the revenue in the year 2021 that was $31.24K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Poseida Therapeutics, Inc. from 2016 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $150.86M 133.15%
2023 $64.70M -50.37%
2022 $130.36M 417,217.08%
2021 $31.24K 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 -100.00%
2017 $2.99M -69.44%
2016 $9.77M 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 8,268.33%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 3,891.36%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 10,336.52%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 1,376.89%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH